ABSTRACT To examine trends in predictors of HIV-related mortality among cohorts of persons living with AIDS (PLWA) in New York
INTRODUCTION
Many studies of survival among persons living with AIDS (PLWA) have focused on cohorts of persons diagnosed with AIDS during a defined calendar period, controlling for factors known to affect survival. 1, 2 Others have examined relative survival time following AIDS diagnosis, controlling for stage of disease. 3, 4 Such approaches
Stage of Disease at AIDS Diagnosis
Persons diagnosed with AIDS were classified as having been diagnosed on the basis of an AIDS-defining OI or immunologic status (CD4 < 200 cells/μL). The first CD4 count within 9 months of the AIDS diagnosis date was used as a marker for the stage of disease at diagnosis.
Vital Status and Cause of Death
The vital status and underlying cause of death of persons reported to the HIV/AIDS Reporting System are updated through quarterly matches with the NYC Vital Statistics registry. Vital status for the study population was current as of December 31, 2002 . Routine (every 2-3 years) matching with the National Death Index is done to ascertain vital status and underlying cause of death on persons diagnosed in NYC who may have subsequently moved and/or died elsewhere in the United States. The last National Death Index match was conducted in March 2002 for deaths through 1999. Deaths were classified as being due to HIV/AIDS or other causes using the International Classification of Diseases, 9th Revision (for deaths in 1993-1999) and 10th Revision (for deaths in [2000] [2001] .
Statistical Methods
For each year-specific cohort, the time-to-event variable was number of years from beginning of a given calendar year (or date of diagnosis if this occurred during that year) to death from an HIV-related cause. Persons who died from causes other than HIV were censored as of their date of death. To be consistent with previous investigations 22 and due to concern about incompleteness of vital status among long-term survivors, persons surviving more than 5 years following AIDS diagnosis were right censored. Cox proportional hazards models were constructed for each cohort to evaluate trends in predictors of mortality over time. Models included sex, race/ethnicity, age at AIDS diagnosis, transmission risk category, borough of residence, stage of disease at AIDS diagnosis, time since AIDS diagnosis, and first CD4 count following AIDS diagnosis. Thus, the maximum follow-up for persons in each cohort ranged from 2 years (2001 cohort) to 5 years (1993-1998 cohorts). The overall median follow-up time was 3.7 years (range, 0.003-5.0). The proportional hazards assumption was tested and met for each year-specific cohort. Statistical analyzes were carried out using SAS software (Version 8.0, Cary, North Carolina).
RESULTS

Epidemiology of PLWA in NYC, 1993-2001
The number of AIDS diagnoses in NYC peaked at 12, 658 (Fig. 1) . Most of the decline occurred in HIVrelated deaths, following the introduction of HAART. This downward trend slowed by 1998 and has not changed appreciably since that time. Table 2 summarizes the annual mortality rate per 1,000 PLWA for all and HIV only-related causes among each year-specific cohort. Both all-cause and HIV-related mortality rates decreased from 1993 to 2001, with a sharp decline beginning in 1995. HIV-related death rates declined at a similar rate for males and females ( Fig. 2a ) and for each race/ethnicity category ( Fig. 2b ) over time. Declines in HIV-related mortality rates occurred in every age group, most notably after 1995 (Fig. 2c ), but PLWA aged 60+ had consistently higher death rates than younger PLWA. In 1993, MSM PLWA had higher death rates per 1,000 PLWA than IDU and heterosexual PLWA, for both all-cause and HIV-related mortality. Although HIV-related death rates subsequently declined in all three transmission risk groups, the decline was greatest among MSM ( Fig. 2d ).
Early disparities in mortality rates based on AIDS diagnosis category converged over time such that there were no apparent differences in death rates by 2001 (Fig. 2f ). Table 3 summarizes cohort-specific adjusted relative risks (ARR) for HIV-related death among selected subgroups. Females were at significantly increased risk compared with males over the latter half of the study period (ARR 1994 = 1.1, ARR 2001 = 1.2) (Fig. 3a) . Beginning in 1996, black and Hispanic PLWA had a significantly higher risk of death than white PLWA, respectively (ARR 2001 = 1.4, ARR 2001 = 1.1) and these differences increased with time ( Fig. 3b ).
Trends in the Adjusted Relative Hazards for Death due to HIV-Related Causes
Compared to PLWA aged 20-29 years, PLWA in older age groups were at significantly increased risk of death. This difference remained relatively steady over time ( Fig. 3c) , except among PLWA aged 60+ whose risk appeared to increase (ARR 1993 = 1.7, ARR 2001 = 2.4).
Transmission risk category was also a significant predictor of survival, with emerging disparities beginning in 1996 and growing over time ( (Fig. 3f) . CD4 count at time of AIDS diagnosis was an important predictor of survival in 1993. However, though still statistically significant, differences in survival by initial CD4 count diminished with time.
Increasing time since AIDS diagnosis was consistently a significant predictor of survival. Before 1997, persons diagnosed with AIDS 1-<4 years prior had significantly poorer survival than persons diagnosed within 1 year. After 1997, PLWA who had been diagnosed for more than one year tended to have significantly better survival experiences than those diagnosed within the year. In each cohort, PLWA 
DISCUSSION
Our analysis indicates that, in the context of marked improvement in both mortality and survival among all PLWA, significant disparities have emerged among specific subgroups coincident with the widespread availability of HAART in 1995-1996. Disparities increased such that as of 2001, females, persons aged 60+, persons of black or Hispanic race/ethnicity, and persons with a history of IDU or heterosexual transmission risk had significantly poorer survival than their counterparts. Disparities in survival appeared to be widening not because death rates were increasing in any one group but primarily because they were not declining proportionally across subgroups. These disparities were seen to be independent of differences in age at AIDS diagnosis, disease stage, CD4 count at diagnosis, or time since diagnosis. Our investigation evaluated trends in the predictors of survival using cohorts of PLWA alive in a given year, rather than cohorts based on stage of disease, year of AIDS diagnosis, or date of HIV seroconversion. This approach provides an alternative method for public health officials to characterize predictors of survival in a population of PLWA at a given point in time, which may be more relevant for some applications since it is an easily definable group in which to follow trends and target interventions. Many differences observed in our study population intensified over time, suggesting that elucidation of the underlying causes of these disparities among subgroups will be necessary to implement effective interventions aimed at reducing such disparities in the near future.
The findings are likely to reflect individual-and population-level differences in a variety of factors that affect survival in persons with HIV/AIDS that have become more apparent in the post-HAART era. Before HAART, the major determinants of survival in HIV patients were age and time since seroconversion. 23 After 1996, factors reported to affect survival include socioeconomic status, 24, 25 access to care, timely initiation of HAART, 26 physicians' experience with caring for HIV/AIDS patients, 27 and adherence to complex medical regimens that may render viral strains therapy-resistant. In a cohort of HIV patients receiving HAART, one report found that neither age nor sex was associated with mortality, 28 suggesting that our results may indeed reflect differential initiation or usage of HAART in older persons and females. Such disparities in utilization of appropriate therapy for HIV have been previously reported 29, 30 and are further suggested from the results of our analysis. Reports are conflicting about sex differences in the natural history of HIV and response to HAART. Some studies have found no sex difference in response to HAART, 31, 32 whereas others suggest that females do better. 33, 34 Our investigation found that females are more likely to die compared with males and is inconsistent with both of these findings. Perhaps female PLWA in NYC are less likely than males to be on HAART.
Among persons with HIV, there has been an overall increase in proportion of patients receiving HAART, 26 however, disparities in therapy initiation or usage among groups based on sociodemographic factors have been reported, with blacks, IDUs, female heterosexuals, persons with lower levels of education, and the uninsured or Medicaid-insured less likely to receive timely therapy or any therapy at all. 26, [35] [36] [37] A study of HIV-positive patients receiving HAART in NYC demonstrated that black race/ethnicity, older age, and low CD4 count had a significant, indepen-dent negative effect on mortality, 38 supporting results observed in other studies that initiation of therapy may be delayed in these groups. Given reports that tripletherapy regimens uniformly decrease HIV RNA levels independent of sex, age, race, or transmission risk group, 28 the differences in survival that we observed may reflect differential access to, usage of, or initiation by providers of these life-prolonging regimens. The pronounced emergence of poorer survival among IDU relative to MSM, independent of other differences controlled for, could be attributed to a combination of a lower likelihood of HAART use or deleterious interaction between illicit drugs and HAART, both of which have been observed elsewhere. 39 Limitations of our analysis must be considered. Differences in outcomes among subgroups might result from biases and confounders not accounted for in our model. We were unable to examine specific factors, such as health insurance, access to and quality of care, or health-related behavior that may account for these disparities on an individual and/or population level. Another limitation is the large proportion of persons missing a CD4 count in the 1993 PLWA cohort. We found in multivariate analysis that missing a CD4 count was independently associated with a higher risk of death. This finding and RRs for the other CD4 count levels in 1993 should be interpreted cautiously as it is possible that no available CD4 count is a marker for other factors such as more severe AIDS defining illness. Following the implementation of HIV (non-AIDS) reporting in June 2000, 21 the completeness of OI reporting may have been reduced, possibly resulting in some misclassification. Perhaps the largest limitation with our analysis is that information on treatment and clinical events, such as HAART initiation or development of an intercurrent illness, was not available for our study population. Finally, the methodological use of successive non-independent year-specific cohorts of PLWA limits the ability to apply statistical tests for trends and differences in RRs from year to year. However, AIDS case reporting in NYC was shown to be highly complete during the study period, 18 and the study population likely includes nearly all PLWA. Therefore, the observed trends may be interpreted with less reliance on statistical inference.
In summary, our analysis documents the emergence of significant disparities in survival among specific subgroups of PLWA in NYC over time, even after adjusting for multiple possible confounding factors. We attribute the observed differences to real differences in survival based on sex, race/ethnicity, and transmission risk group that likely reflect differential access to or utilization of medical services. The results of this investigation are highly generalizable to PLWA in NYC, given the high completeness of AIDS case reporting 18 and the large number of persons included in our analysis. Given the societal burden of HIV/AIDS in years of potential life lost, 40 future research and interventions must be targeted toward continued reduction of HIV/AIDS-related mortality and more definitive research studies regarding the specific factors that contribute to survival disparities are needed. Such efforts should be directed toward mitigating external factors that impact health and access to medical care and treatment.
